Tegoprazan for heartburn and regurgitation in NERD: Phase III trial

Summaries 2 min 591

Font Size

Created On: 04/02/2026

Tegoprazan is a next-generation potassium-competitive acid blocker (P-CAB) with a rapid onset and sustained acid suppression.

See All

Key take away

Tegoprazan (both 50 mg and 100 mg) improves heartburn and regurgitation resolution while maintaining a favorable safety profile in patients with NERD.

Background

Tegoprazan is a next-generation potassium-competitive acid blocker (P-CAB) with a rapid onset and sustained acid suppression. By effectively diminishing gastric acid secretion, tegoprazan offers a promising treatment option for non-erosive reflux disease (NERD), a common and challenging subtype of gastroesophageal reflux disease (GERD). This phase III study scrutinized the clinical efficacy and safety of tegoprazan compared with placebo in Korean adults diagnosed with NERD.

Method

In this randomized controlled trial, 324 NERD sufferers were allocated to receive tegoprazan 50 mg, tegoprazan 100 mg, or placebo once daily for about 4 weeks. The key endpoint was complete resolution of key GERD symptoms—heartburn and regurgitation—during the final 7 days of treatment. Secondary endpoints encompassed additional symptom relief measures, safety, and drug tolerability.

Result

Overall, a higher proportion of patients treated with tegoprazan (both 50 mg and 100 mg) achieved complete resolution of major symptoms at week 4 compared with those receiving placebo (Table 1).

Rates of heartburn resolution and the proportion of heartburn-free days were also markedly higher with tegoprazan than with placebo (P < 0.05 for all comparisons). The occurrence of treatment-emergent adverse events was similar across all groups, depicting good safety and tolerability.

Conclusion

Tegoprazan 50 mg and 100 mg offered substantially better symptom control than placebo in patients with NERD, with a favorable safety profile. These findings support tegoprazan as an effective and well-tolerated acid suppression therapy for NERD and reinforce its potential role in modern GERD care.